What the research found

Researchers analysed how AGGF1, a protein involved in blood vessel formation, influences blood pressure regulation—particularly through its effects on the endothelium (the inner lining of blood vessels). They found that AGGF1 declines both with age and in people with hypertension, suggesting it may protect against age-related pressure increases.

In mouse studies, animals lacking functional AGGF1 developed high blood pressure by 11 months of age, whereas those engineered to produce extra human AGGF1 showed substantially delayed and reduced blood pressure elevation even at 25 months. The protective effect was specific to endothelium-dependent vessel relaxation—the mechanism by which healthy vessel linings allow blood vessels to dilate. Additionally, AGGF1 appeared to reduce oxidative stress (reactive oxygen species production), a hallmark of vascular aging.

The mechanism appears to work through a downstream protein called SESN2. In cultured human endothelial cells, low AGGF1 correlated with cellular senescence markers, DNA damage, and inflammation. Increasing SESN2 expression could partially rescue these effects, and directly manipulating SESN2 levels in mice confirmed it was essential for AGGF1's blood pressure benefits.

Why it matters for you

Blood pressure sits at the intersection of ageing and cardiometabolic health for most MyKine users. While the study doesn't yet translate to a supplement or peptide you can take, it identifies a specific cellular pathway—the AGGF1/SESN2 axis—that appears to fail during ageing and drive prehypertension. This is relevant to how you think about vascular function independent of just resting BP readings.

If you track endothelial biomarkers (flow-mediated dilation, pulse wave velocity, or inflammatory markers like IL-6), this work suggests they may reflect declining AGGF1 activity. Similarly, if you monitor oxidative stress via urinary 8-OHdG or blood biomarkers, the ROS reduction in AGGF1-high animals hints at why antioxidant interventions sometimes show modest benefits in hypertension. The pathway also connects to training adaptations: endothelium-dependent relaxation improves with aerobic exercise, and AGGF1 may be part of why.

For now, this is foundational science. It opens the door to future AGGF1-targeted therapies or SESN2 activators, but does not suggest changing current protocols.

Caveats

  • Animal and cellular work only: findings in mice and lab-grown human cells do not automatically translate to living humans
  • Male mice only: sex differences in endothelial function and AGGF1 regulation remain unknown
  • Mechanism incomplete: the study does not explain why AGGF1 declines with age, limiting insights into prevention
  • No human dose-response data: no information on whether modulating AGGF1 in humans would produce similar effects or at what dose